{"title":"Real-World Persistence on Tofacitinib in Psoriatic Arthritis Patients With Enthesitis: Comments on Recent Findings.","authors":"Joaquín Borrás-Blasco,Alejandro Valcuende-Rosique,Silvia Cornejo-Uixeda","doi":"10.3899/jrheum.2025-0722","DOIUrl":"https://doi.org/10.3899/jrheum.2025-0722","url":null,"abstract":"","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"175 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144857745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Peter Xie,Michael Oliffe,Geraldine Hassett,David Massasso
{"title":"Crystalline Deposition in a Nose With a Sinus Tract.","authors":"Peter Xie,Michael Oliffe,Geraldine Hassett,David Massasso","doi":"10.3899/jrheum.2025-0439","DOIUrl":"https://doi.org/10.3899/jrheum.2025-0439","url":null,"abstract":"","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"5 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144857741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Bahram Razani,Vinod Chandran,Kurt de Vlam,Wilson Liao,Barbara A Malynn,Averil Ma
{"title":"A New Mouse Model of Psoriatic Arthritis.","authors":"Bahram Razani,Vinod Chandran,Kurt de Vlam,Wilson Liao,Barbara A Malynn,Averil Ma","doi":"10.3899/jrheum.2025-0528","DOIUrl":"https://doi.org/10.3899/jrheum.2025-0528","url":null,"abstract":"Polymorphisms in the TNFAIP3 locus encoding the A20 protein are strongly associated with psoriatic skin and joint disease. Reduced A20 expression, driven by both genetic and epigenetic factors, underscores its critical role as a negative regulator of psoriatic disease (PsD). Our recent study using a germline knockin mouse model harboring a mutation in A20's seventh zinc finger, which impairs A20 binding to linear (M1) ubiquitin, revealed a spontaneous phenotype resembling psoriatic arthritis. These mice demonstrated sustained nuclear factor-κB signaling in response to transient tumor necrosis factor stimulation, leading to inappropriate transcription of mid- and late-response inflammatory genes. These findings highlight the role of dysregulated innate immune-signaling kinetics as a potential driver of PsD pathogenesis. These findings, together with distinct inflammatory mouse models resulting from temporally extended inflammatory gene activation, highlight the role of dysregulated innate immune-signaling kinetics as a potential driver of tissue inflammation with relevance to psoriatic skin and joint disease. This newly developed mouse model of PsD was presented at the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2024 annual meeting.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"294 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144857753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Gizem Ayan,M Elaine Husni,Ashish J Mathew,Iain B McInnes,Philip J Mease
{"title":"GRAPPA 2024: Innovations in Education Workshop.","authors":"Gizem Ayan,M Elaine Husni,Ashish J Mathew,Iain B McInnes,Philip J Mease","doi":"10.3899/jrheum.2025-0240","DOIUrl":"https://doi.org/10.3899/jrheum.2025-0240","url":null,"abstract":"At the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2024 annual meeting and trainee symposium, an Innovations in Education workshop aimed to explore the skills necessary to design learning objectives, optimize artificial intelligence (AI) use in education, and employ interactive teaching methods. Learning objectives are crucial for structuring educational programs and enhancing learner engagement and performance. Although incorporating AI into education promises untapped potential, it requires careful implementation to avoid introducing inaccuracies and biases. Effective teaching techniques, such as the Know-Feel-Do principle, emphasize the importance of understanding audience needs, creating engaging content, and fostering interactive learning environments. With the use of real-world examples in the rheumatology field, the workshop illustrated the diversity and impact of innovative educational practices that can help educators deliver an outstanding learning experience. This paper will cover the key points from this workshop.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"8 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144857736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Andre L Ribeiro,Gizem Ayan,Hanna J Johnsson,Roxana Coras,Michelle Mulder,Daniela B Tovar-Bastidas,Dimitri L F Silva,Arani Vivekanantham,Fabian Proft
{"title":"Young-GRAPPA 2024: Progress, Achievements, and Strategic Developments.","authors":"Andre L Ribeiro,Gizem Ayan,Hanna J Johnsson,Roxana Coras,Michelle Mulder,Daniela B Tovar-Bastidas,Dimitri L F Silva,Arani Vivekanantham,Fabian Proft","doi":"10.3899/jrheum.2025-0263","DOIUrl":"https://doi.org/10.3899/jrheum.2025-0263","url":null,"abstract":"The Young Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (Y-GRAPPA) was established in 2021. As of July 2024, the group consists of 152 members, featuring a balanced gender distribution and a 70/30 split between rheumatology and dermatology specialties. In the last year, Y-GRAPPA updated its major project-the GRAPPA slide library-to include translations in 5 new languages, continued to publish the \"Do Not Miss\" newsletters, and presented \"Virtual Highlights\" for major international conferences (American Academy of Dermatology [AAD] annual meeting, European Alliance of Associations for Rheumatology [EULAR] annual congress, European Academy of Dermatology and Venereology [EADV] congress, and American College of Rheumatology [ACR] Convergence). Presently, Y-GRAPPA is boosting social media presence and refining its organizational structure and activities. This includes restructuring committees with new leaders to each focus on specific objectives, streamlined leadership, and proactive member recruitment and engagement. The key objective of Y-GRAPPA remains to ensure active participation in all GRAPPA activities through collaboration and communication between Y-GRAPPA and senior GRAPPA members.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"24 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144857743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pamela Díaz,Walter P Maksymowych,Mikkel Østergaard
{"title":"How to Identify and Monitor Axial and Peripheral Psoriatic Arthritis by Magnetic Resonance Imaging.","authors":"Pamela Díaz,Walter P Maksymowych,Mikkel Østergaard","doi":"10.3899/jrheum.2025-0433","DOIUrl":"https://doi.org/10.3899/jrheum.2025-0433","url":null,"abstract":"Psoriatic arthritis (PsA) is characterized by a spectrum of clinical manifestations. Magnetic resonance imaging (MRI) is a crucial tool in elucidating inflammatory and structural lesions associated with both peripheral and axial forms of the disease. The implementation of standardized definitions and scoring systems for active and structural MRI lesions facilitates a rigorous evaluation of axial and peripheral joint involvement and enthesitis in patients with PsA. Further, the emerging potential of whole-body MRI techniques shows promise in differentiating treatment effects. The annual MRI workshop, held at the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2024 meeting in Seattle, Washington, USA, aimed to underscore the significant role of MRI in the comprehensive assessment of PsA manifestations. Through the presentation of interactive case studies, the workshop illustrated the practical applications of MRI in the clinical management of individuals with PsA, enhancing understanding of its diagnostic capabilities and highlighting its contributions to treatment strategies.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"31 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144787213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Andre L Ribeiro,Tommy Kok Annfeldt,Dafna D Gladman,William Tillett,Ana-Maria Orbai,Ying Ying Leung
{"title":"Composite Outcome Measures for Psoriatic Arthritis: Project Updates 2024.","authors":"Andre L Ribeiro,Tommy Kok Annfeldt,Dafna D Gladman,William Tillett,Ana-Maria Orbai,Ying Ying Leung","doi":"10.3899/jrheum.2025-0268","DOIUrl":"https://doi.org/10.3899/jrheum.2025-0268","url":null,"abstract":"The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)-Outcome Measures in Rheumatology (OMERACT) psoriatic arthritis (PsA) working group provided updates at the GRAPPA 2024 annual meeting on their assessment of composite outcome measures for PsA. The group presented the progress of a systematic literature review on the psychometric properties of the following candidate composite outcome measures using the OMERACT filter 2.2: (1) minimal disease activity (MDA), (2) Disease Activity for Psoriatic Arthritis (DAPSA), (3) American College of Rheumatology (ACR) response criteria, (4) Psoriatic Arthritis Disease Activity Score (PASDAS), (5) Composite Psoriatic Disease Activity Index (CPDAI), (6) 3-item visual analog scale (3VAS), and (7) 4VAS. A Delphi exercise for patient research partners (PRPs) on domain match and feasibility is ongoing. Following analysis and endorsement of domain match and feasibility by PRPs, the working group will seek endorsement from the GRAPPA community. In addition, the group illustrated a new research proposal for using network metaanalysis to quantitatively compare the responsiveness of these various composite outcome measures.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"728 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144787214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lyn Chinchay,Kaiyang Song,Jeffrey Stark,Nicole L Ward,Iain B McInnes
{"title":"Challenges and Opportunities in Psoriatic Disease: An Integrated View of the Future.","authors":"Lyn Chinchay,Kaiyang Song,Jeffrey Stark,Nicole L Ward,Iain B McInnes","doi":"10.3899/jrheum.2025-0264","DOIUrl":"https://doi.org/10.3899/jrheum.2025-0264","url":null,"abstract":"Psoriatic disease (PsD), which includes cutaneous psoriasis (PsO) and psoriatic arthritis (PsA), affects 2% of the global population, and results in the development of comorbidities that adversely affect quality of life (QOL) and physical function. Recent advances in the field have allowed for earlier diagnosis of PsD and improved clinical strategies for care, including the use of innovative pathway-specific immune-targeted therapies. Despite these advances, there is no cure for PsD. Ongoing challenges in disease management include the need for adequate treatment response, precision-based care for individual patients, and a better understanding of the interrelationship between the pathogenesis of cutaneous PsO and PsO comorbidities, including PsA. Future progress may arise from integrating clinical disciplines, harnessing artificial intelligence, using molecular dissection to map out the disease pathogenesis of PsA to identify more effective treatment strategies, and exploring the interplay between PsD and comorbidities including cardiovascular disease, obesity, and depression. These developments could lead to personalized treatment approaches and increase the efficacy of therapeutics for PsD, ultimately improving patient outcomes and QOL. This article highlights the presentation of this topic at the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2024 annual meeting.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"21 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144787223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Huidi Shucheng,April W Armstrong,Liv Eidsmo,Denis Poddubnyy
{"title":"Hot Topics: Exploring Artificial Intelligence and Inflammatory Memory in the Management of Psoriatic Diseases.","authors":"Huidi Shucheng,April W Armstrong,Liv Eidsmo,Denis Poddubnyy","doi":"10.3899/jrheum.2025-0241","DOIUrl":"https://doi.org/10.3899/jrheum.2025-0241","url":null,"abstract":"The \"hot topics\" session of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2024 annual meeting and trainee symposium explored the integration of artificial intelligence (AI) in managing psoriatic diseases (PsD) and the underlying mechanisms of inflammatory memory that drive recurrence in psoriasis and psoriatic arthritis. Drs. April Armstrong and Denis Poddubnyy discussed the transformative role of AI in enhancing diagnostic accuracy, assessing disease severity, and predicting treatment responses, particularly through deep learning models such as convolutional neural networks. AI systems have shown promise in providing objective, standardized assessments for psoriasis, with applications expanding across dermatology and rheumatology. Dr. Liv Eidsmo presented insights into inflammatory memory, a phenomenon sustained by both immune and nonimmune cells, including tissue-resident memory cells and epigenetically altered keratinocytes. Eidsmo emphasized the importance of understanding the cellular and molecular pathways that contribute to disease persistence. Both AI and inflammatory memory highlight key challenges and opportunities in PsD management; future research is needed to integrate technological advancements, with a deeper understanding of the biological processes affecting treatment outcomes.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"10 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144787390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Andrea Leung,Kerem Abacar,Georgia Marquez-Grap,Allison Kranyak,Wilson Liao,Dennis McGonagle
{"title":"MHC-I-opathy: A Unified Concept for the Etiology of Several Major Histocompatibility Complex-Associated Conditions Including Psoriasis and Psoriatic Arthritis.","authors":"Andrea Leung,Kerem Abacar,Georgia Marquez-Grap,Allison Kranyak,Wilson Liao,Dennis McGonagle","doi":"10.3899/jrheum.2025-0235","DOIUrl":"https://doi.org/10.3899/jrheum.2025-0235","url":null,"abstract":"At the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2024 annual meeting, Drs. Dennis McGonagle and Wilson Liao discussed \"MHC-I-opathies,\" a class of immune-mediated diseases genetically associated with major histocompatibility complex class I (MHC-I) and class I peptide processing. MHC-I-opathies demonstrate epistatic interactions, genetic associations, and immunopathology that are distinct from classic B cell and autoantibody-driven autoimmune diseases. Investigations into the pathomechanisms of MHC-I-opathies have revealed a blend of tissue-specific innate immunity and CD8 T cell responses. Several functional pathomechanisms by which MHC-I molecules increase psoriasis (PsO) susceptibility were presented by McGonagle and Liao, and there were multiple associations within the HLA-C locus. Antigen presentation to T cells, HLA regulation of natural killer cells and CD8 T cells through killer immunoglobulin-like receptors, and HLA regulation of dendritic cells through leukocyte immunoglobulin-like receptors were discussed. Interestingly, MHC-I associations are not only linked to excessive inflammation in MHC-I-opathies but also to the spontaneous suppression of infection (eg, HIV-1 elite controllers). This striking prominence of MHC-I in PsO and antiviral immunity provides insight into why autoimmune alleles are maintained in the human genome and how protective antiviral pathways may be linked to aberrant activation of MHC-I-opathies. Outside of spinal inflammation in HLA-B27-positive axial psoriatic arthritis (PsA), the basis for MHC-I genetics in PsA remains less clear and is at least partly linked to greater PsA heterogeneity. Understanding the contribution of MHC-I in PsO and PsA may have important implications for therapy development.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"15 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144787215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}